The Fight Against COVID19
20.05k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
Performance
| Watchlist | Change today | 1-month return | 1-year return | Total return |
|---|---|---|---|---|
| The Fight Against COVID19 | +5.54% | - | - | - |
| ^GSPC | +1.95% | -1.88% | +29.25% | +4031.12% |
14 symbols
| Symbol | Company name | Last price | Change | % change | Market time | Volume | Avg vol (3-month) | Market cap |
|---|---|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 156.1 | +3.03 | +1.98% | 4:00 pm GMT-5 | 8.33M | 8.28M | 410.34B |
| PFE | Pfizer Inc. | 34.39 | +0.19 | +0.56% | 4:02 pm GMT-5 | 30.56M | 40.07M | 191.81B |
| ABBV | AbbVie Inc. | 106.7 | +1.05 | +0.99% | 4:02 pm GMT-5 | 7.01M | 7.22M | 188.42B |
| SNY | Sanofi | 46.59 | +0.69 | +1.50% | 4:00 pm GMT-5 | 3.17M | 2.80M | 117.23B |
| GSK | GlaxoSmithKline plc | 34.91 | +0.63 | +1.84% | 4:00 pm GMT-5 | 6.44M | 5.61M | 87.34B |
| GILD | Gilead Sciences, Inc. | 64.62 | +1.39 | +2.20% | 4:00 pm GMT-5 | 9.76M | 9.11M | 81.20B |
| TAK | Takeda Pharmaceutical Company Limited | 17.47 | +0.03 | +0.17% | 4:00 pm GMT-5 | 3.24M | 3.85M | 55.75B |
| MRNA | Moderna, Inc. | 132.19 | -0.11 | -0.08% | 4:00 pm GMT-5 | 12.04M | 18.39M | 52.85B |
| REGN | Regeneron Pharmaceuticals, Inc. | 461.57 | +12.19 | +2.71% | 4:00 pm GMT-5 | 1.13M | 1.04M | 49.45B |
| BNTX | BioNTech SE | 96.2 | +1.05 | +1.10% | 4:00 pm GMT-5 | 1.69M | 2.83M | 23.16B |
| NVAX | Novavax, Inc. | 174.84 | +16.74 | +10.59% | 4:00 pm GMT-5 | 5.77M | 4.67M | 12.91B |
| VIR | Vir Biotechnology, Inc. | 45.18 | +5.51 | +13.89% | 4:00 pm GMT-5 | 2.13M | 1.75M | 5.78B |
| INO | Inovio Pharmaceuticals, Inc. | 9.19 | +0.04 | +0.44% | 4:00 pm GMT-5 | 15.28M | 15.63M | 1.91B |
- Editor's pickYahoo Finance
China, Russia playing 'greater-than-expected' roles in global pandemic response
The world grapples with the expected tug-of-war between wealthy and poorer nations over vaccine supplies, paving the way for U.S. adversaries.
- Editor's pickYahoo Finance
Why 'vaccine passports' could be complicated to pull off in the US
While international governments are rolling out credentialing systems designed for their citizens to prove they’ve been inoculated against COVID-19, the concept of a government-mandated “vaccine passport” could be a non-starter in the U.S., due to legal and, perhaps more so, pragmatic barriers.
- Barrons.com
SPAC Market ‘Mania’ Could Spell Trouble
Valuations are inflating, and terms offered to investors continue to deteriorate, says Marketfield Asset Management. Plus, investment-newsletter commentary on the February jobs report, Europe’s debt woes, and travel stocks
